Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Modulation of Micrornas by Aspirin in Cardiovascular Disease Publisher Pubmed



Paseban M1 ; Marjaneh RM2 ; Banach M3, 4 ; Riahi MM5 ; Bo S6 ; Sahebkar A7, 8, 9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
  3. 3. Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland
  4. 4. Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland
  5. 5. Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Department of Medical Sciences, AOU Citta della Salute e della Scienza di Torino, University of Turin, Torino, Italy
  7. 7. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
  8. 8. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  9. 9. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Trends in Cardiovascular Medicine Published:2020


Abstract

Aspirin is among the most widely prescribed drugs in cardiovascular and cerebrovascular diseases for both primary and secondary prevention. The major mechanisms underlying its benefits are the inhibitory effects on platelet activation and prostanoid biosynthesis induced by COX-1 and COX-2 inactivation. MicroRNAs (miRNAs) are newly proposed mediators of the effects of aspirin. In this review, we summarize the evidence on the links between miRNAs and aspirin use in relation to cardiovascular diseases. In addition, we discuss the studies suggesting a possible role for miRNAs as biomarkers of aspirin resistance, a condition during which atherothrombotic events occur despite aspirin use, and which affects a considerable proportion of patients with cardiovascular disease. © 2019 Elsevier Inc.
Other Related Docs
14. Plasminogen Activator Inhibitor Type-1 As a Regulator of Fibrosis, Journal of Cellular Biochemistry (2018)
20. Green Tea and Its Anti-Angiogenesis Effects, Biomedicine and Pharmacotherapy (2017)
24. Microrna: A Novel Target of Curcumin in Cancer Therapy, Journal of Cellular Physiology (2018)
29. Micrornas As the Actors in the Atherosclerosis Scenario, Journal of Physiology and Biochemistry (2020)
35. Microrna: Relevance to Stroke Diagnosis, Prognosis, and Therapy, Journal of Cellular Physiology (2018)
40. Microrna Profiles in Critically Ill Patients, Current Medicinal Chemistry (2024)
45. Role of Micrornas in Pulmonary Hypertension, Horizons in World Cardiovascular Research (2022)